ADB, IMEXPHARM sign loan to support generic medicine production in Vietnam

	ADB allocates $20 Million to help developing members access vaccines for COVID-19
	Vietnam starts COVID-19 vaccine trials on monkeys
	Success comes with passion for scientific research

Imexpharm Corporation

The financing will support the company’s working capital needs to ensure ample supply of active pharmaceutical ingredients for essential generic medicine production. Imexpharm’s operations and continued production of generic pharmaceuticals and their ensured availability in the market is integral in safeguarding the country’s health care during the pandemic.

“Asia has witnessed disruptions across the pharmaceutical supply chain in 2020, including a shortage of active pharmaceutical ingredients,” said Head of Health and Education Investments at ADB's Private Sector Operations Department Aniruddha Patil. “This project demonstrates ADB’s continued efforts to enhance health outcomes in Viet Nam by encouraging the development and use of local generic medicines.”

“We are pleased to be working with ADB,” said Imexpharm’s Chairman Nguyen Quoc Dinh. “The financing will improve our liquidity situation and ensure a consistent supply of affordable generic drugs to hospitals and pharmacies across Viet Nam.”

This debt financing is part of ADB’s $20 billion assistance announced on 13 April to help its developing members manage the pandemic.

ADB provides $ 600,000 grant to support Vietnam's Covid-19 response VCN - The Asian Development Bank (ADB) has provided a $600,000 grant in-kind to assist the Government ...

Imexpharm was established in 1977 and initially incorporated in 1983 as the Dong Thap Pharmaceutical Union. The firm was transformed from a state-owned enterprise into a joint-stock company and renamed Imexpharm Corporation, and its shares were listed on the Ho Chi Minh Stock Exchange on 4 December 2006. As of 30 September 2020, Imexpharm had 1,252 employees, total assets of 2.072 billion VND and 6 pharmaceutical manufacturing facilities.